To find the adequate dose of carbetocin during cesarean surgery in patients of preeclampsia, with and without magnesium sulfate therapy
Phase 4
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2024/04/066205
- Lead Sponsor
- niversity College of Medical Sciences and GTBH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Non-laboring parturients, with preeclampsia (with or without magnesium sulfate therapy scheduled for cesarean delivery under spinal block
Exclusion Criteria
Patient refusal, presence of active labor (defined as cervical dilatation of 4 cm or more), preoperative use of oxytocin, or other conditions predisposing to PPH i.e., history of previous PPH, chorioamnionitis, macrosomia, more than two previous uterine surgery, previous history of bleeding disorders, and presence of abnormal placentation/uterine fibroid; as well as use of general anesthesia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The ED90 dose (dose effective in 90% population) for satisfactory uterine tone as judged by the obstetricianTimepoint: 2 minutes after carbetocin injection, and then till end of surgery.
- Secondary Outcome Measures
Name Time Method Carbetocin associated side effects like hypotension, tachycardiaTimepoint: From administration of carbetocin to 10 minutes later.